Provided by Tiger Trade Technology Pte. Ltd.

PELTHOS THERAPEUTICS INC

21.45
-0.4900-2.23%
Volume:36.95K
Turnover:805.62K
Market Cap:82.12M
PE:-0.81
High:22.20
Open:21.51
Low:21.25
Close:21.94
52wk High:37.50
52wk Low:18.19
Shares:3.83M
Float Shares:1.07M
Volume Ratio:1.30
T/O Rate:3.47%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-26.3603
EPS(LYR):-23.0359
ROE:-333.84%
ROA:-49.98%
PB:-54.71
PE(LYR):-0.93

Loading ...

Pelthos Therapeutics files Form 3 for CFO John M. Gay

Reuters
·
Apr 21

Pelthos CEO to hold investor meetings at Piper Sandler Spring Biopharma Symposium

Reuters
·
Apr 14

BRIEF-Pelthos Therapeutics Announces CFO Transition

Reuters
·
Apr 11

Pelthos names John Gay CFO, replacing Francis Knuettel II

Reuters
·
Apr 11

Pelthos Therapeutics Inc - Appoints John M. Gay as CFO Effective April 10, 2026

THOMSON REUTERS
·
Apr 11

Top Premarket Decliners

MT Newswires Live
·
Apr 07

Analysts Offer Insights on Healthcare Companies: Pelthos Therapeutics (PTHS), IDEAYA Biosciences (IDYA) and Viridian Therapeutics (VRDN)

TIPRANKS
·
Apr 06

Pelthos Therapeutics doses first patient in CT2000 trial

TIPRANKS
·
Mar 31

BRIEF-Pelthos Therapeutics Announces First Patient Dosed In Phase 1B/2A Clinical Trial Of Ct2000 In Eye Pain

Reuters
·
Mar 31

Pelthos Therapeutics Announces First Patient Dosed in Phase 1B/2a Clinical Trial of Ct2000 in Eye Pain

THOMSON REUTERS
·
Mar 31

Pelthos Therapeutics Inc - Results From Phase 1B/2a Ct2000 Trial Anticipated at End of 2026

THOMSON REUTERS
·
Mar 31

Alliance Global Partners Keeps Their Buy Rating on Pelthos Therapeutics (PTHS)

TIPRANKS
·
Mar 30

Pelthos Therapeutics Inc trading resumes

TIPRANKS
·
Mar 23

Analysts Offer Insights on Healthcare Companies: Community Health (CYH) and Pelthos Therapeutics (PTHS)

TIPRANKS
·
Mar 22

Lake Street Sticks to Their Buy Rating for Pelthos Therapeutics (PTHS)

TIPRANKS
·
Mar 20

Pelthos Therapeutics Inc. : Oppenheimer Raises Target Price to $62 From $60

THOMSON REUTERS
·
Mar 20

BRIEF-Pelthos Therapeutics Announces Fourth Quarter And Full Year 2025 Financial Results

Reuters
·
Mar 19

Pelthos Q4 net loss widens to USD 21.66 million as ZELSUVMI net product revenue rises 28% to USD 9.09 million

Reuters
·
Mar 19

Refile- Pelthos Therapeutics Inc Qtrly Total Revenue $9.4 Mln (Adds Dropped Currency)

THOMSON REUTERS
·
Mar 19

Pelthos Therapeutics Inc: Have Commercial Infrastructure and Experience to Continue to Grow Zelsuvmi and Launch and Grow Xepi and Xeglyze

THOMSON REUTERS
·
Mar 19